Literature DB >> 12702571

HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.

Frank Loganzo1, Carolyn M Discafani, Tami Annable, Carl Beyer, Sylvia Musto, Malathi Hari, Xingzhi Tan, Carolyn Hardy, Richard Hernandez, Michelle Baxter, Thiruvikraman Singanallore, Gulnaz Khafizova, Marianne S Poruchynsky, Tito Fojo, James A Nieman, Semiramis Ayral-Kaloustian, Arie Zask, Raymond J Andersen, Lee M Greenberger.   

Abstract

Hemiasterlin is a natural product derived from marine sponges that, like other structurally diverse peptide-like molecules, binds to the Vinca-peptide site in tubulin, disrupts normal microtubule dynamics, and, at stoichiometric amounts, depolymerizes microtubules. Total synthesis of hemiasterlin and its analogues has been accomplished, and optimal pharmacological features of the series have been explored. The biological profile of one analogue, HTI-286, was studied here. HTI-286 inhibited the polymerization of purified tubulin, disrupted microtubule organization in cells, and induced mitotic arrest, as well as apoptosis. HTI-286 was a potent inhibitor of proliferation (mean IC(50) = 2.5 +/- 2.1 nM in 18 human tumor cell lines) and had substantially less interaction with multidrug resistance protein (P-glycoprotein) than currently used antimicrotubule agents, including paclitaxel, docetaxel, vinorelbine, or vinblastine. Resistance to HTI-286 was not detected in cells overexpressing the drug transporters MRP1 or MXR. In athymic mice implanted with human tumor xenografts, HTI-286 administered i.v. in saline inhibited the growth of numerous human tumors derived from carcinoma of the skin, breast, prostate, brain, and colon. Marked tumor regression was observed when used on established tumors that were >1 gram in size. Moreover, HTI-286 inhibited the growth of human tumor xenografts (e.g., HCT-15, DLD-1, MX-1W, and KB-8-5) where paclitaxel and vincristine were ineffective because of inherent or acquired resistance associated with P-glycoprotein. Efficacy was also achieved with p.o. administration of HTI-286. These data suggest that HTI-286 has excellent preclinical properties that may translate into superior clinical activity, as well as provide a useful synthetic reagent to probe the drug contact sites of peptide-like molecules that interact with tubulin.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12702571

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

1.  Nature's medicines: traditional knowledge and intellectual property management. Case studies from the National Institutes of Health (NIH), USA.

Authors:  Ranjan Gupta; Bjarne Gabrielsen; Steven M Ferguson
Journal:  Curr Drug Discov Technol       Date:  2005-12

Review 2.  Drug development from marine natural products.

Authors:  Tadeusz F Molinski; Doralyn S Dalisay; Sarah L Lievens; Jonel P Saludes
Journal:  Nat Rev Drug Discov       Date:  2008-12-19       Impact factor: 84.694

Review 3.  Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy.

Authors:  Kinsie E Arnst; Souvik Banerjee; Hao Chen; Shanshan Deng; Dong-Jin Hwang; Wei Li; Duane D Miller
Journal:  Med Res Rev       Date:  2019-02-11       Impact factor: 12.944

4.  Novel microtubule-targeted agent 6-chloro-4-(methoxyphenyl) coumarin induces G2-M arrest and apoptosis in HeLa cells.

Authors:  Yi-ming Ma; Yu-bo Zhou; Chuan-ming Xie; Dong-mei Chen; Jia Li
Journal:  Acta Pharmacol Sin       Date:  2012-01-23       Impact factor: 6.150

5.  Hemiasterlin analogues incorporating an aromatic, and heterocyclic type C-terminus: design, synthesis and biological evaluation.

Authors:  Giordano Lesma; Alessandro Sacchetti; Rouli Bai; Giuseppe Basso; Roberta Bortolozzi; Ernest Hamel; Alessandra Silvani; Nadia Vaiana; Giampietro Viola
Journal:  Mol Divers       Date:  2014-02-06       Impact factor: 2.943

6.  The Impact of Treatment Preferences in Second-Line Chemotherapy on the Prognosis of HER2-Negative Metastatic Breast Cancer.

Authors:  Hirofumi Mukai; Yasuhiro Hagiwara; Kentaro Imi; Hirotsugu Isaka; Kenichi Watanabe; Yutaka Matsuyama
Journal:  Oncology       Date:  2017-08-24       Impact factor: 2.935

7.  Complementary isonitrile-based multicomponent reactions for the synthesis of diversified cytotoxic hemiasterlin analogues.

Authors:  Giordano Lesma; Ivan Bassanini; Roberta Bortolozzi; Chiara Colletto; Ruoli Bai; Ernest Hamel; Fiorella Meneghetti; Giulia Rainoldi; Mattia Stucchi; Alessandro Sacchetti; Alessandra Silvani; Giampietro Viola
Journal:  Org Biomol Chem       Date:  2015-10-15       Impact factor: 3.876

Review 8.  Marine natural product peptides with therapeutic potential: Chemistry, biosynthesis, and pharmacology.

Authors:  Vedanjali Gogineni; Mark T Hamann
Journal:  Biochim Biophys Acta Gen Subj       Date:  2017-08-24       Impact factor: 3.770

9.  Biological evaluation of tubulysin A: a potential anticancer and antiangiogenic natural product.

Authors:  Gurmeet Kaur; Melinda Hollingshead; Susan Holbeck; Vesna Schauer-Vukasinović; Richard F Camalier; Alexander Dömling; Seema Agarwal
Journal:  Biochem J       Date:  2006-06-01       Impact factor: 3.857

10.  Mitochondrial dysfunction confers resistance to multiple drugs in Caenorhabditis elegans.

Authors:  Iryna O Zubovych; Sarah Straud; Michael G Roth
Journal:  Mol Biol Cell       Date:  2010-01-20       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.